Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Jun;21(6):713–719. doi: 10.1111/j.1365-2125.1986.tb05237.x

Effect of nadolol on liver haemodynamics and function in patients with cirrhosis.

C Merkel, D Sacerdoti, G F Finucci, R Zuin, G Bazzerla, M Bolognesi, A Gatta
PMCID: PMC1400973  PMID: 3741719

Abstract

Beta-adrenoceptor blockers used in the medical management of portal hypertension decrease liver blood flow. The sporadic onset of hepatic encephalopathy during propranolol treatment was ascribed to this decrease. The aim of the present study was to evaluate the effect of chronic treatment with nadolol on liver blood flow and liver function. Nadolol, a non-cardioselective beta-adrenoceptor blocker, has been reported to be as powerful as propranolol in decreasing portal pressure. Before and after 1 month of treatment with nadolol at a dose reducing heart rate by 25%, in 15 cirrhotic patients with portal hypertension, the following parameters were determined: hepatic venous pressure gradient, hepatic blood flow, galactose eliminating capacity, aminopyrine metabolic activity, ICG clearance and intrinsic hepatic clearance. Hepatic venous pressure gradient and hepatic blood flow were decreased by nadolol. However liver function was not affected by the drug. We conclude that, despite a lowered hepatic blood flow, liver function is not affected by 1 month of nadolol treatment.

Full text

PDF
713

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbare J. C., Poupon R., Jaillon P., Bories P., Aussanaire M., Darnis F., Michel H., Cheymol G. The influence of vasoactive agents on metabolic activity of the liver in cirrhosis: a study of the effects of posterior pituitary extract, vasopressin, and somatostatin. Hepatology. 1984 Jan-Feb;4(1):59–62. doi: 10.1002/hep.1840040110. [DOI] [PubMed] [Google Scholar]
  2. Braillon A., Jirón M. I., Valla D., Calès P., Lebrec D. Effect of propranolol on hepatic blood flow in patients with cirrhosis. Clin Pharmacol Ther. 1985 Apr;37(4):376–380. doi: 10.1038/clpt.1985.57. [DOI] [PubMed] [Google Scholar]
  3. CAESAR J., SHALDON S., CHIANDUSSI L., GUEVARA L., SHERLOCK S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961 Aug;21:43–57. [PubMed] [Google Scholar]
  4. Dagradi A. E. Esophageal varices, splenic pulp pressure and "directional" flow patterns in alcoholic liver cirrhosis. Am J Gastroenterol. 1973 Jan;59(1):15–22. [PubMed] [Google Scholar]
  5. Gatta A., Sacerdoti D., Merkel C., Milani L., Battaglia G., Zuin R. Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension. Am Heart J. 1984 Oct;108(4 Pt 2):1167–1172. doi: 10.1016/0002-8703(84)90602-1. [DOI] [PubMed] [Google Scholar]
  6. Hepner G. W., Vesell E. S. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med. 1975 Nov;83(5):632–638. doi: 10.7326/0003-4819-83-5-632. [DOI] [PubMed] [Google Scholar]
  7. Hillon P., Blanchet L., Lebrec D. Effect of propranolol on hepatic blood flow in normal and portal hypertensive rats. Clin Sci (Lond) 1982 Jul;63(1):29–32. doi: 10.1042/cs0630029. [DOI] [PubMed] [Google Scholar]
  8. Keiding S., Chiarantini E. Effect of sinusoidal perfusion on galactose elimination kinetics in perfused rat liver. J Pharmacol Exp Ther. 1978 May;205(2):465–470. [PubMed] [Google Scholar]
  9. Lebrec D., Hillon P., Muńoz C., Goldfarb G., Nouel O., Benhamou J. P. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology. 1982 Sep-Oct;2(5):523–527. doi: 10.1002/hep.1840020502. [DOI] [PubMed] [Google Scholar]
  10. Levitt M. D., Levitt D. G. Intrinsic hepatic clearance in cirrhosis. Gastroenterology. 1978 Aug;75(2):346–348. [PubMed] [Google Scholar]
  11. Merkel C., Gatta A., Zuin R., Finucci G. F., Nosadini R., Ruol A. Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. Digestion. 1985;32(2):92–98. doi: 10.1159/000199224. [DOI] [PubMed] [Google Scholar]
  12. O'Connor D. T., Barg A. P., Duchin K. L. Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol. J Clin Pharmacol. 1982 Apr;22(4):187–195. doi: 10.1002/j.1552-4604.1982.tb02161.x. [DOI] [PubMed] [Google Scholar]
  13. Pessayre D., Lebrec D., Descatoire V., Peignoux M., Benhamou J. P. Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology. 1978 Mar;74(3):566–571. [PubMed] [Google Scholar]
  14. TYGSTRUP N. Determination of the hepatic galactose elimination capacity after a single intravenous injection in man: the reproducibility and the influence of uneven distribution. Acta Physiol Scand. 1963 Jun-Jul;58:162–172. doi: 10.1111/j.1748-1716.1963.tb02638.x. [DOI] [PubMed] [Google Scholar]
  15. Tarver D., Walt R. P., Dunk A. A., Jenkins W. J., Sherlock S. Precipitation of hepatic encephalopathy by propranolol in cirrhosis. Br Med J (Clin Res Ed) 1983 Aug 27;287(6392):585–585. doi: 10.1136/bmj.287.6392.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Westaby D., Bihari D. J., Gimson A. E., Crossley I. R., Williams R. Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut. 1984 Feb;25(2):121–124. doi: 10.1136/gut.25.2.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]
  18. Winchell H. S., Stahelin H., Kusubov N., Slanger B., Fish M., Pollycove M., Lawrence J. H. Kinetics of CO2-HCO3 minus in normal adult males. J Nucl Med. 1970 Dec;11(12):711–715. [PubMed] [Google Scholar]
  19. van Buuren H. R., van der Velden P. C., Koorevaar G., Silberbusch J. Propranolol increases arterial ammonia in liver cirrhosis. Lancet. 1982 Oct 30;2(8305):951–952. doi: 10.1016/s0140-6736(82)90158-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES